Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Global Anxiety Disorders Market 2015-2019

Published: Jan-2015 | Format: PDF | Technavio | Number of pages: 73 | Code: MRS - 3607

 

Anxiety is associated with uneasiness, fearfulness, and tension. Mild anxiety, for example, associated with exams or interview, is normal and triggers ''fight or flight'' response. Anxiety without an identifiable cause, anxiety which persists even after the stressful condition is over, and anxiety which is out of proportion of the stressful condition indicates abnormal anxiety. However, severe and persistent anxiety can interfere with everyday activities and might lead to other psychic problems. Anxiety disorder is a mental health disorder characterized by the presence of anxiety. These disorders might occur simultaneously with other disorders such as depression, or along with drug abuse.

 

TechNavio''s analysts forecast the Global Anxiety Disorders market to grow at a CAGR of 4.02 percent over the period 2014-2019.

 

Covered in this Report
 

This report covers the present scenario and the growth prospects of the Global Anxiety Disorders market for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of the following anxiety disorders:

 

GAD
Panic Disorder
OCD
PTSD
Social Anxiety Disorder
Special Phobias
BDD

 

The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Anxiety Disorders market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

 

TechNavio''s report, Global Anxiety Disorders Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Anxiety Disorders market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

 

Key Regions
 

Americas
APAC
EMEA

 

Key Vendors
 

Eli Lilly and Company
GlaxoSmithKline
Pfizer
 

Other Prominent Vendors

 

Abbott Laboratories
Actavis
Baxter International
F. Hoffmann-La Roche
Noven Pharmaceuticals
Recordati Rare Diseases
Shionogi
Sumitomo Dainippon Pharma


Market Driver
 

Increase in Patient Population
For a full, detailed list, view our report

 

Market Challenge
 

Poor Diagnoses Rates
For a full, detailed list, view our report

 

Market Trend
 

Increased Focus on Emerging Markets
For a full, detailed list, view our report

 

Key Questions Answered in this Report
 

What will the market size be in 2019 and what will the growth rate be
What are the key market trends
What is driving this market
What are the challenges to market growth
Who are the key vendors in this market space
What are the market opportunities and threats faced by the key vendors
What are the strengths and weaknesses of the key vendors

Table of Contents

 

1. Executive Summary
 

2. List of Abbreviations
 

3. Scope of the Report
3.1 Market Overview
3.2 Product Offerings

 

4. Market Research Methodology
4.1 Market Research Process
4.2 Research Methodology

 

5. Introduction
 

6. Types of anxiety disorders
 

7. Market Landscape
7.1 Market Overview
7.2 Market Size and Forecast
7.3 Five Forces Analysis

 

8. Market Segmentation by Drug Class
 

9. Geographical Segmentation
 

10. Buying Criteria
 

11. Market Growth Drivers
 

12. Drivers and their Impact
 

13. Market Challenges
 

14. Impact of Drivers and Challenges
 

15. Market Trends
 

16. Trends and their Impact
 

17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Eli Lilly
17.2.2 Pfizer
17.2.3 GlaxoSmithKline
17.3 Other Prominent Vendors

 

18. Key Vendor Analysis
18.1 Eli Lilly
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue
18.1.4 Sales by Geography
18.1.5 Business Strategy
18.1.6 Key Information
18.1.7 SWOT Analysis
18.2 GlaxoSmithKline 
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Pipeline Products
18.2.7 Business Strategy
18.2.8 Key Information
18.2.9 SWOT Analysis
18.3 Pfizer
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2013
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Geographical Segmentation by Revenue
18.3.6 Business Strategy
18.3.7 Key Developments
18.3.8 SWOT Analysis

 

19. Other Reports in this Series
 

List of Exhibits
 

Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Anxiety Disorders
Exhibit 3: GAD: Disease Overview
Exhibit 4: Panic Disorder: Disease Overview
Exhibit 5: OCD: Disease Overview
Exhibit 6: PTSD: Disease Overview
Exhibit 7: Social Anxiety Disorder: Disease Overview
Exhibit 8: Specific Phobias: Disease Overview
Exhibit 9: BDD: Disease Overview
Exhibit 10: Global Anxiety Disorders Market 2014-2019 (US$ billion)
Exhibit 11: Global Anxiety Disorders Market Segmentation by Drug Class
Exhibit 12: Segmentation of Global Anxiety Disorders Market by Geography 2014
Exhibit 13: Cymbalta: Basic Information
Exhibit 14: Cymbalta Revenue 2011-9M 2014 (US$ million)
Exhibit 15: Revenue Segmentation by Geography 9M 2014
Exhibit 16: Pfizer: Revenue of Key Anti-Anxiety Products 9M 2014 (US$ million)
Exhibit 17: Lyrica: Basic Information
Exhibit 18: Lyrica Revenue 2011-9M 2014 (US$ million)
Exhibit 19: Revenue Segmentation by Geography 9M 2014
Exhibit 20: Zoloft: Basic Information
Exhibit 21: Zoloft Revenue 2011-9M 2014 (US$ million)
Exhibit 22: Revenue Segmentation by Geography 9M 2014
Exhibit 23: Effexor and Effexor XR: Basic Information
Exhibit 24: Effexor/Effexor XR Revenue 2011-9M 2014 (US$ million)
Exhibit 25: Revenue Segmentation by Geography 9M 2014
Exhibit 26: Xanax and Xanax XR: Basic Information
Exhibit 27: Xanax/Xanax XR Revenue 2011-9M 2014 (US$ million)
Exhibit 28: Revenue Segmentation by Geography 9M 2014
Exhibit 29: Seroxat/Paxil/Paxil CR: Basic Information
Exhibit 30: Seroxat/Paxil Revenue 2011-9M 2014 (US$ million)
Exhibit 31: Revenue Segmentation by Geography 9M 2014
Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 34: Eli Lilly: Sales by Geography 2013
Exhibit 35: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 36: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 37: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 38: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 39: Pfizer: Business Segmentation by Revenue 2013
Exhibit 40: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 41: Pfizer: Geographical Segmentation by Revenue 2013 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2500 View Pricing